Role of natural mTOR inhibitors in treatment of diabetes mellitus
Diabetes mellitus is one of the most common and complex problems in today's society and is responsible for many socio‐economic problems. Type 1 diabetes is due to a defect in insulin secretion caused by a destruction of pancreatic β cells. In contrast, the pathogenesis of type 2 diabetes is ass...
Gespeichert in:
Veröffentlicht in: | Fundamental & clinical pharmacology 2023-06, Vol.37 (3), p.461-479 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 479 |
---|---|
container_issue | 3 |
container_start_page | 461 |
container_title | Fundamental & clinical pharmacology |
container_volume | 37 |
creator | Noori, Tayebeh Sureda, Antoni Shirooie, Samira |
description | Diabetes mellitus is one of the most common and complex problems in today's society and is responsible for many socio‐economic problems. Type 1 diabetes is due to a defect in insulin secretion caused by a destruction of pancreatic β cells. In contrast, the pathogenesis of type 2 diabetes is associated with the development of insulin resistance in the liver and peripheral tissues, a decrease in β‐cell mass, and a defect in insulin secretion. Various factors such as inflammation, stress, obesity, and lifestyle are involved in diabetes. Long‐term or chronic increase in glucose in these patients is the leading causes of secondary disorders such as micro‐ and macro‐angiopathy, weakness of the antioxidant defense system, and metabolic disorders and altered lipid profile. The above conditions lead to short‐term and long‐term complications. These complications cause damage to the physical and physiological function of diverse organs of the body and threaten human health. Late complications of diabetes, including nephropathy, retinopathy, cardiovascular complications, neuropathy, hypertension, and weight gain, are common, and more research has been done on them. Numerous drugs such as meglitinides, biguanides, and thiazolidinedione have been proposed to reduce high blood sugar, but due to the lack of complete cure of this disease with the use of existing drugs, the tendency to use alternative and traditional therapies has increased. In the meantime, the role of herbs with hypoglycemic properties in the treatment of diabetic patients cannot be ignored. The consumption of herbs by people with diabetes has become widespread even in Western countries. The use of herbs could be considered when conventional therapies cannot control the disease, and the patient needs to be prescribed insulin. The mammalian target of rapamycin, mTOR, plays a significant role in regulating cell growth, cellular metabolic status in response to nutrients, many extracellular cues, and growth factors. Impaired insulin secretion can lead to altered mTOR signaling. The mTOR pathway has shown different behaviors depending on the situation. It has been shown that mTOR can regulate the adaptation of β cells to blood sugar, and chronic inhibition of the mTOR pathway can also induce diabetes. Here, we have reviewed recent findings on the role of mTOR in major metabolic organs, such as the liver, pancreas, brain, and adipose tissue and muscle, and discussed its potential as a diabetes‐related drug targ |
doi_str_mv | 10.1111/fcp.12851 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2739430262</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2811746628</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3531-fdb3e179fccf712a35ea9a04b38f4e1d546ecd6e7e9d57f564fa10f056a4e1b23</originalsourceid><addsrcrecordid>eNp10M9LwzAUB_AgipvTg_-AFLzooVte0ibtUYZTYTAZ8xzS9gU7-mMmLbL_3sxOD4Lvkgf58OXxJeQa6BT8zEy-mwJLYjghY4gkCxNGxSkZUylkyNMERuTCuS2lICmIczLiIoI4FcmYPKzbCoPWBI3uequroN6s1kHZvJdZ2bXW-TXoLOquxqY7uKLUGXboghqrqux6d0nOjK4cXh3fCXlbPG7mz-Fy9fQyf1iGOY85hKbIOIJMTZ4bCUzzGHWqaZTxxEQIRRwJzAuBEtMiliYWkdFADY2F9t8Z4xNyN-TubPvRo-tUXbrcH6EbbHunmORpxCkTB3r7h27b3jb-OsUSABkJwRKv7geV29Y5i0btbFlru1dA1aFX5XtV3716e3NM7LMai1_5U6QHswF8lhXu_09Si_nrEPkFAPGAsg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2811746628</pqid></control><display><type>article</type><title>Role of natural mTOR inhibitors in treatment of diabetes mellitus</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Noori, Tayebeh ; Sureda, Antoni ; Shirooie, Samira</creator><creatorcontrib>Noori, Tayebeh ; Sureda, Antoni ; Shirooie, Samira</creatorcontrib><description>Diabetes mellitus is one of the most common and complex problems in today's society and is responsible for many socio‐economic problems. Type 1 diabetes is due to a defect in insulin secretion caused by a destruction of pancreatic β cells. In contrast, the pathogenesis of type 2 diabetes is associated with the development of insulin resistance in the liver and peripheral tissues, a decrease in β‐cell mass, and a defect in insulin secretion. Various factors such as inflammation, stress, obesity, and lifestyle are involved in diabetes. Long‐term or chronic increase in glucose in these patients is the leading causes of secondary disorders such as micro‐ and macro‐angiopathy, weakness of the antioxidant defense system, and metabolic disorders and altered lipid profile. The above conditions lead to short‐term and long‐term complications. These complications cause damage to the physical and physiological function of diverse organs of the body and threaten human health. Late complications of diabetes, including nephropathy, retinopathy, cardiovascular complications, neuropathy, hypertension, and weight gain, are common, and more research has been done on them. Numerous drugs such as meglitinides, biguanides, and thiazolidinedione have been proposed to reduce high blood sugar, but due to the lack of complete cure of this disease with the use of existing drugs, the tendency to use alternative and traditional therapies has increased. In the meantime, the role of herbs with hypoglycemic properties in the treatment of diabetic patients cannot be ignored. The consumption of herbs by people with diabetes has become widespread even in Western countries. The use of herbs could be considered when conventional therapies cannot control the disease, and the patient needs to be prescribed insulin. The mammalian target of rapamycin, mTOR, plays a significant role in regulating cell growth, cellular metabolic status in response to nutrients, many extracellular cues, and growth factors. Impaired insulin secretion can lead to altered mTOR signaling. The mTOR pathway has shown different behaviors depending on the situation. It has been shown that mTOR can regulate the adaptation of β cells to blood sugar, and chronic inhibition of the mTOR pathway can also induce diabetes. Here, we have reviewed recent findings on the role of mTOR in major metabolic organs, such as the liver, pancreas, brain, and adipose tissue and muscle, and discussed its potential as a diabetes‐related drug target.</description><identifier>ISSN: 0767-3981</identifier><identifier>EISSN: 1472-8206</identifier><identifier>DOI: 10.1111/fcp.12851</identifier><identifier>PMID: 36415968</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adipose tissue ; Beta cells ; Blood glucose ; Blood Glucose - metabolism ; Body weight gain ; Cell growth ; Complications ; Defects ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (insulin dependent) ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - metabolism ; Diabetic neuropathy ; Disease control ; glucose ; Growth factors ; Health risks ; Herbs ; Humans ; Hyperglycemia ; Hypertension ; Hypoglycemic Agents - pharmacology ; Hypoglycemic Agents - therapeutic use ; Insulin ; Insulin resistance ; Insulin secretion ; Lipids ; Liver ; Metabolic disorders ; Metabolism ; mTOR ; MTOR Inhibitors ; natural products ; Nephropathy ; Nutrients ; Organs ; Pathogenesis ; Pharmacology ; Rapamycin ; Retinopathy ; Secretion ; Sugar ; Therapeutic targets ; TOR protein ; TOR Serine-Threonine Kinases - metabolism</subject><ispartof>Fundamental & clinical pharmacology, 2023-06, Vol.37 (3), p.461-479</ispartof><rights>2022 Société Française de Pharmacologie et de Thérapeutique.</rights><rights>2023 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3531-fdb3e179fccf712a35ea9a04b38f4e1d546ecd6e7e9d57f564fa10f056a4e1b23</citedby><cites>FETCH-LOGICAL-c3531-fdb3e179fccf712a35ea9a04b38f4e1d546ecd6e7e9d57f564fa10f056a4e1b23</cites><orcidid>0000-0002-5000-3387</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Ffcp.12851$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Ffcp.12851$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36415968$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Noori, Tayebeh</creatorcontrib><creatorcontrib>Sureda, Antoni</creatorcontrib><creatorcontrib>Shirooie, Samira</creatorcontrib><title>Role of natural mTOR inhibitors in treatment of diabetes mellitus</title><title>Fundamental & clinical pharmacology</title><addtitle>Fundam Clin Pharmacol</addtitle><description>Diabetes mellitus is one of the most common and complex problems in today's society and is responsible for many socio‐economic problems. Type 1 diabetes is due to a defect in insulin secretion caused by a destruction of pancreatic β cells. In contrast, the pathogenesis of type 2 diabetes is associated with the development of insulin resistance in the liver and peripheral tissues, a decrease in β‐cell mass, and a defect in insulin secretion. Various factors such as inflammation, stress, obesity, and lifestyle are involved in diabetes. Long‐term or chronic increase in glucose in these patients is the leading causes of secondary disorders such as micro‐ and macro‐angiopathy, weakness of the antioxidant defense system, and metabolic disorders and altered lipid profile. The above conditions lead to short‐term and long‐term complications. These complications cause damage to the physical and physiological function of diverse organs of the body and threaten human health. Late complications of diabetes, including nephropathy, retinopathy, cardiovascular complications, neuropathy, hypertension, and weight gain, are common, and more research has been done on them. Numerous drugs such as meglitinides, biguanides, and thiazolidinedione have been proposed to reduce high blood sugar, but due to the lack of complete cure of this disease with the use of existing drugs, the tendency to use alternative and traditional therapies has increased. In the meantime, the role of herbs with hypoglycemic properties in the treatment of diabetic patients cannot be ignored. The consumption of herbs by people with diabetes has become widespread even in Western countries. The use of herbs could be considered when conventional therapies cannot control the disease, and the patient needs to be prescribed insulin. The mammalian target of rapamycin, mTOR, plays a significant role in regulating cell growth, cellular metabolic status in response to nutrients, many extracellular cues, and growth factors. Impaired insulin secretion can lead to altered mTOR signaling. The mTOR pathway has shown different behaviors depending on the situation. It has been shown that mTOR can regulate the adaptation of β cells to blood sugar, and chronic inhibition of the mTOR pathway can also induce diabetes. Here, we have reviewed recent findings on the role of mTOR in major metabolic organs, such as the liver, pancreas, brain, and adipose tissue and muscle, and discussed its potential as a diabetes‐related drug target.</description><subject>Adipose tissue</subject><subject>Beta cells</subject><subject>Blood glucose</subject><subject>Blood Glucose - metabolism</subject><subject>Body weight gain</subject><subject>Cell growth</subject><subject>Complications</subject><subject>Defects</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (insulin dependent)</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Diabetic neuropathy</subject><subject>Disease control</subject><subject>glucose</subject><subject>Growth factors</subject><subject>Health risks</subject><subject>Herbs</subject><subject>Humans</subject><subject>Hyperglycemia</subject><subject>Hypertension</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Insulin secretion</subject><subject>Lipids</subject><subject>Liver</subject><subject>Metabolic disorders</subject><subject>Metabolism</subject><subject>mTOR</subject><subject>MTOR Inhibitors</subject><subject>natural products</subject><subject>Nephropathy</subject><subject>Nutrients</subject><subject>Organs</subject><subject>Pathogenesis</subject><subject>Pharmacology</subject><subject>Rapamycin</subject><subject>Retinopathy</subject><subject>Secretion</subject><subject>Sugar</subject><subject>Therapeutic targets</subject><subject>TOR protein</subject><subject>TOR Serine-Threonine Kinases - metabolism</subject><issn>0767-3981</issn><issn>1472-8206</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10M9LwzAUB_AgipvTg_-AFLzooVte0ibtUYZTYTAZ8xzS9gU7-mMmLbL_3sxOD4Lvkgf58OXxJeQa6BT8zEy-mwJLYjghY4gkCxNGxSkZUylkyNMERuTCuS2lICmIczLiIoI4FcmYPKzbCoPWBI3uequroN6s1kHZvJdZ2bXW-TXoLOquxqY7uKLUGXboghqrqux6d0nOjK4cXh3fCXlbPG7mz-Fy9fQyf1iGOY85hKbIOIJMTZ4bCUzzGHWqaZTxxEQIRRwJzAuBEtMiliYWkdFADY2F9t8Z4xNyN-TubPvRo-tUXbrcH6EbbHunmORpxCkTB3r7h27b3jb-OsUSABkJwRKv7geV29Y5i0btbFlru1dA1aFX5XtV3716e3NM7LMai1_5U6QHswF8lhXu_09Si_nrEPkFAPGAsg</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Noori, Tayebeh</creator><creator>Sureda, Antoni</creator><creator>Shirooie, Samira</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5000-3387</orcidid></search><sort><creationdate>202306</creationdate><title>Role of natural mTOR inhibitors in treatment of diabetes mellitus</title><author>Noori, Tayebeh ; Sureda, Antoni ; Shirooie, Samira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3531-fdb3e179fccf712a35ea9a04b38f4e1d546ecd6e7e9d57f564fa10f056a4e1b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adipose tissue</topic><topic>Beta cells</topic><topic>Blood glucose</topic><topic>Blood Glucose - metabolism</topic><topic>Body weight gain</topic><topic>Cell growth</topic><topic>Complications</topic><topic>Defects</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (insulin dependent)</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Diabetic neuropathy</topic><topic>Disease control</topic><topic>glucose</topic><topic>Growth factors</topic><topic>Health risks</topic><topic>Herbs</topic><topic>Humans</topic><topic>Hyperglycemia</topic><topic>Hypertension</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Insulin secretion</topic><topic>Lipids</topic><topic>Liver</topic><topic>Metabolic disorders</topic><topic>Metabolism</topic><topic>mTOR</topic><topic>MTOR Inhibitors</topic><topic>natural products</topic><topic>Nephropathy</topic><topic>Nutrients</topic><topic>Organs</topic><topic>Pathogenesis</topic><topic>Pharmacology</topic><topic>Rapamycin</topic><topic>Retinopathy</topic><topic>Secretion</topic><topic>Sugar</topic><topic>Therapeutic targets</topic><topic>TOR protein</topic><topic>TOR Serine-Threonine Kinases - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noori, Tayebeh</creatorcontrib><creatorcontrib>Sureda, Antoni</creatorcontrib><creatorcontrib>Shirooie, Samira</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Fundamental & clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noori, Tayebeh</au><au>Sureda, Antoni</au><au>Shirooie, Samira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of natural mTOR inhibitors in treatment of diabetes mellitus</atitle><jtitle>Fundamental & clinical pharmacology</jtitle><addtitle>Fundam Clin Pharmacol</addtitle><date>2023-06</date><risdate>2023</risdate><volume>37</volume><issue>3</issue><spage>461</spage><epage>479</epage><pages>461-479</pages><issn>0767-3981</issn><eissn>1472-8206</eissn><abstract>Diabetes mellitus is one of the most common and complex problems in today's society and is responsible for many socio‐economic problems. Type 1 diabetes is due to a defect in insulin secretion caused by a destruction of pancreatic β cells. In contrast, the pathogenesis of type 2 diabetes is associated with the development of insulin resistance in the liver and peripheral tissues, a decrease in β‐cell mass, and a defect in insulin secretion. Various factors such as inflammation, stress, obesity, and lifestyle are involved in diabetes. Long‐term or chronic increase in glucose in these patients is the leading causes of secondary disorders such as micro‐ and macro‐angiopathy, weakness of the antioxidant defense system, and metabolic disorders and altered lipid profile. The above conditions lead to short‐term and long‐term complications. These complications cause damage to the physical and physiological function of diverse organs of the body and threaten human health. Late complications of diabetes, including nephropathy, retinopathy, cardiovascular complications, neuropathy, hypertension, and weight gain, are common, and more research has been done on them. Numerous drugs such as meglitinides, biguanides, and thiazolidinedione have been proposed to reduce high blood sugar, but due to the lack of complete cure of this disease with the use of existing drugs, the tendency to use alternative and traditional therapies has increased. In the meantime, the role of herbs with hypoglycemic properties in the treatment of diabetic patients cannot be ignored. The consumption of herbs by people with diabetes has become widespread even in Western countries. The use of herbs could be considered when conventional therapies cannot control the disease, and the patient needs to be prescribed insulin. The mammalian target of rapamycin, mTOR, plays a significant role in regulating cell growth, cellular metabolic status in response to nutrients, many extracellular cues, and growth factors. Impaired insulin secretion can lead to altered mTOR signaling. The mTOR pathway has shown different behaviors depending on the situation. It has been shown that mTOR can regulate the adaptation of β cells to blood sugar, and chronic inhibition of the mTOR pathway can also induce diabetes. Here, we have reviewed recent findings on the role of mTOR in major metabolic organs, such as the liver, pancreas, brain, and adipose tissue and muscle, and discussed its potential as a diabetes‐related drug target.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36415968</pmid><doi>10.1111/fcp.12851</doi><tpages>19</tpages><orcidid>https://orcid.org/0000-0002-5000-3387</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0767-3981 |
ispartof | Fundamental & clinical pharmacology, 2023-06, Vol.37 (3), p.461-479 |
issn | 0767-3981 1472-8206 |
language | eng |
recordid | cdi_proquest_miscellaneous_2739430262 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Adipose tissue Beta cells Blood glucose Blood Glucose - metabolism Body weight gain Cell growth Complications Defects Diabetes Diabetes mellitus Diabetes mellitus (insulin dependent) Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - metabolism Diabetic neuropathy Disease control glucose Growth factors Health risks Herbs Humans Hyperglycemia Hypertension Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Insulin Insulin resistance Insulin secretion Lipids Liver Metabolic disorders Metabolism mTOR MTOR Inhibitors natural products Nephropathy Nutrients Organs Pathogenesis Pharmacology Rapamycin Retinopathy Secretion Sugar Therapeutic targets TOR protein TOR Serine-Threonine Kinases - metabolism |
title | Role of natural mTOR inhibitors in treatment of diabetes mellitus |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T03%3A58%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20natural%20mTOR%20inhibitors%20in%20treatment%20of%20diabetes%20mellitus&rft.jtitle=Fundamental%20&%20clinical%20pharmacology&rft.au=Noori,%20Tayebeh&rft.date=2023-06&rft.volume=37&rft.issue=3&rft.spage=461&rft.epage=479&rft.pages=461-479&rft.issn=0767-3981&rft.eissn=1472-8206&rft_id=info:doi/10.1111/fcp.12851&rft_dat=%3Cproquest_cross%3E2811746628%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2811746628&rft_id=info:pmid/36415968&rfr_iscdi=true |